REYON Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 15, 2022 at 02:49 am EST
Share
REYON Pharmaceutical Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 0.00016 million compared to KRW 0.00012 million a year ago. Net income was KRW 2,087.92 million compared to KRW 14.46 million a year ago. Basic earnings per share from continuing operations was KRW 116 compared to KRW 1 a year ago. Basic earnings per share was KRW 116 compared to KRW 1 a year ago.
For the nine months, negative sales was KRW 0.00016 million compared to sales of KRW 0.00044 million a year ago. Net income was KRW 3,569.03 million compared to KRW 4,071.62 million a year ago. Basic earnings per share from continuing operations was KRW 196 compared to KRW 230 a year ago. Basic earnings per share was KRW 196 compared to KRW 230 a year ago.
REYON PHARMACEUTICAL Co. Ltd. is a Korea-based company engaged in the provision of pharmaceutical products. The Companyâs products consist of remedies for circulatory systems, endocrine systems, digestive systems, respiratory systems, urinary systems and nervous systems, as well as eye drops, antibiotics, fever reducers, painkillers, anti-inflammatory drugs, antihistaminic agents, enzyme preparations, arthritis remedies, antitumor drugs and topical anesthetics, among others. It also produces pharmaceutical raw materials, such as arbekacin sulfate, alibendol, carvedilol, enocitabine, gemcitabine, glimepiride, lamotrigine, meloxicam, oxaliplatin, pioglitazone hydrochloride, ramipril, streptokinase, tacrolimus, thioctic acid, teicoplanin, voglibose and others.
REYON PHARMACEUTICAL CO., LTD. 
